Impaired Innate COPD Alveolar Macrophage Responses and Toll-Like Receptor-9 Polymorphisms

Charles S Berenson1, Ragina L Kruzel1, Catherine T Wrona2

  • 1Division of Infectious Diseases, Department of Veterans Affairs Western New York Healthcare System, State University of New York at Buffalo School of Medicine, Buffalo, New York, 14215, United States of America.

Plos One
|September 12, 2015
PubMed
Abstract

Insights

Specific Toll-like receptor 9 (TLR9) polymorphisms are linked to impaired immune responses in chronic obstructive pulmonary disease (COPD) patients. This TLR9(T1237C) variant is associated with reduced macrophage function and disease severity in COPD.

Area of Science:

  • Immunology
  • Pulmonology
  • Genetics

Background:

  • Dysfunctional innate immune responses in alveolar macrophages contribute to chronic obstructive pulmonary disease (COPD) morbidity.
  • Impaired macrophage responses to Toll-like receptor (TLR) ligands in COPD warrant further investigation of TLR signaling.
  • Single nucleotide polymorphisms (SNPs) in TLRs are increasingly recognized in inflammatory diseases, with recent exploration in COPD.

Purpose of the Study:

  • To investigate the association between specific TLR polymorphisms (TLR2, TLR4, TLR9) and dysfunctional innate immune responses in COPD alveolar macrophages.
  • To determine if TLR polymorphisms correlate with COPD severity and impaired responses to common respiratory pathogens.

Main Methods:

  • DNA was purified from healthy nonsmokers, COPD ex-smokers, and COPD active smokers.
  • Polymerase chain reaction was used to amplify specific single nucleotide polymorphisms (SNPs) in TLR2, TLR4, and TLR9.
  • Alveolar macrophages were incubated with nontypeable H. influenzae, M. catarrhalis, and S. pneumoniae to measure cytokine induction and assess association with TLR SNP expression.

Main Results:

  • No significant inter-group differences in the frequency of any tested TLR SNP were found.
  • Both TLR9 single nucleotide polymorphisms (SNPs) were expressed at high frequencies.
  • Among COPD ex-smokers, diminished IL-8 responsiveness to respiratory pathogens was strongly associated with TLR9(T1237C) carriage (p = 0.02; p = 0.008; p = 0.02), but not TLR9(T1486C).
  • Carriage of TLR9(T1237C), but not TLR9(T1486C), correlated with diminished FEV1%predicted (p = 0.037).

Conclusions:

  • TLR9(T1237C) expression is notably associated with dysfunctional innate alveolar macrophage responses to key respiratory pathogens.
  • The TLR9(T1237C) polymorphism is linked to increased severity of chronic obstructive pulmonary disease (COPD).

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
5.1K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
112